Unresolved Issues in the Treatment of Squamous Cell Carcinoma of the Esophagus. Brief Report

Bakhulova A. M.
Head, Chemotherapeutic Department of the Day Hospital¹

Melnichuk O. V.
Oncologist, Day Hospital Department¹

1 - Moscow Medical Oncological Center, JSC European Medical Center, Moscow, Russian Federation

Bakhulova Aishat; e-mail: Ajshat-89@mail.ru

Authors have no conflict of interest.

The study had no sponsorship.

In recent years, chemotherapy for esophageal cancer has undergone significant changes. The emergence of new immunotherapeutic drugs has created new lines of therapy and significantly improved overall survival and progression-free survival rates in these patients. However, not all patients currently have access to modern treatments. Unfortunately, there is limited published data on the distribution of patients across different therapy options, as well as on treatment choices for patients in later lines of therapy. This article provides an overview of the available data on patient distribution across therapy lines and options.

esophageal cancer, immunotherapy, modern cancer treatment, esophageal cancer statistics

10.29234/2308-9113-2024-13-1-65-72

1. Mandard A.M., Hainaut P., Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res. 2000; 462(2-3): 335-342, doi: 10.1016/s1383-5742(00)00019-3

2. Ford S.J., Bedford M.R., Pang W., et al. A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy. Ann R Coll Surg Engl. 2014; 96(4): 275-278, doi: 10.1308/003588414X13946184900282

3. Yang F., Hu Y., Shi Z., et al. The occurrence and development mechanisms of esophageal stricture: state of the art review. J Transl Med. 2024; 22(1): 123, doi: 10.1186/s12967-024-04932-2

4. Nesteruk K., Spaander M.C.W., Leeuwenburgh I., et al. Achalasia and associated esophageal cancer risk: What lessons can we learn from the molecular analysis of Barrett's–associated adenocarcinoma? Biochim Biophys Acta Rev Cancer 2019; 1872(2): 188291, doi: 10.1016/j.bbcan.2019.04.007

5. Liu H., Yang X., Liu L., et al. Incidental detection of sinonasal inverted papilloma with 68Ga-FAPI PET/CT in a patient with esophageal cancer. Clin Nucl Med. 2021; 46(10): 845-846, doi: 10.1097/RLU.0000000000003733

6. Quante M., Wang T.C., Bass A.J. Adenocarcinoma of the oesophagus: is it gastric cancer? Gut. 2023; 72(6): 1027-1029, doi: 10.1136/gutjnl-2022-327096

7. Zhang X., Yang X., Zhang T., et al. Association of educational attainment with esophageal cancer, Barrett's esophagus, and gastroesophageal reflux disease, and the mediating role of modifiable risk factors: A Mendelian randomization study. Front Public Health. 2023; 11. 1022367, doi: 10.3389/fpubh.2023.1022367

8. Ajani J.A., D'Amico T.A., Bentrem D.J., et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023; 21(4): 393-422, doi: 10.6004/jnccn.2023.0019

9. Yamamoto S., Kato K. Immuno-oncology for esophageal cancer Future Oncol. 2020; 16(32): 2673-2681, doi: 10.2217/fon-2020-0545

10. Yang H., Wang F., Hallemeier C.L., et al. Oesophageal cancer. The Lancet 2024; 404(10466): 1991-2005, 10.1016/S0140-6736(24)02226-8

11. Rak pishchevoda i kardii. Klinicheskie rekomendacii. [Cancer of the esophagus and cardia. Clinical recommendations] Moscow: Ministry of Health of the Russian Federation. 2024 (In Russ.)

12. Fedyanin M.Yu., Tryakin A.A., Rays A.B., et al. Meta-analiz issledovanij effektivnosti dobavleniya anti-PD1 antitel k himioterapii pervoj linii rasprostranyonnogo raka pishchevoda. [Meta-Analysis of Studies on the Effectiveness of Adding Anti-Pd1 Antibodies to the First-Line Chemotherapy In Advanced Esophageal Cancer.] Zlokachestvennye opuholi [Malignant Tumors] 2023; 13(2): 29-55, doi: 10.18027/2224-5057-2023-13-2-3. (In Russ.)